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Abstract
Photodynamic therapy (PDT) is a promising therapeutic modality which uses a photosensitizer to capture visible light
resulting in phototoxicity in the irradiated region. PDT has been used in a number of pathological indications, including
tumor. A key desirable feature of the photosensitizer is the high phototoxicity on tumor cells but not on normal cells. In this
study, we conjugate a gonadotropin-releasing hormone (GnRH) to a photosensitizer, Zinc phthalocyanine (ZnPc), in order to
enhance its specificity to breast cancer, which over-expresses GnRH receptor. ZnPc has unique advantages over other
photosensitizers, but is difficult to derivatize and purify as a single isomer. We previously developed a straight-forward way
to synthesize mono-substituted b-carboxy-phthalocyanine zinc (ZnPc-COOH). Photophysical and photochemical parameters
of this ZnPc-GnRH conjugate including fluorescence quantum yield (Ff), fluorescence decay time (ts) and singlet oxygen
quantum yield (FD) were evaluated and found comparable with that of ZnPc, indicating that addition of a GnRH peptide
does not significantly alter the generation of singlet oxygen from ZnPc. Cellular uptakes and phototoxicities of this
conjugate were tested and found significantly enhanced on human breast cancer cell lines overexpressing GnRH receptors
(MDA-MB-231 and MCF-7 cells) compared to cells with low levels of GnRH receptors, such as human embryonic lung
fibroblast (HELF) and human liver carcinoma (HepG2) cells. In addition, the cellular uptake of this conjugate toward MCF-7
cells were found clearly alleviated by a GnRH receptor blocker Cetrorelix, suggesting that the cellular uptake of this
conjugate was GnRH receptor-mediated. Put together, these findings revealed that coupling ZnPc with GnRH analogue was
an effective way to improve the selectivity of ZnPc towards tumors with over-expressed GnRH receptors.
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Introduction
Cancer is a leading cause of death and a major public health
problem worldwide. A WHO report on global cancer in 2008
pointed out that more than 70% of all cancer deaths occurred in
low- and middle-income countries [1]. Deaths from cancer
worldwide are projected to continue to rise to over 11 million in
2030 [1]. Traditional cancer treatments, including surgery,
radiation therapy and chemotherapy, can cause serious side
effects resulted from the damage of normal cells around.
Photodynamic therapy (PDT) is regarded as a new promising
cancer treatment modality, which typically involves the intrave-
nous injection of a photosensitizer and the illumination by a visible
light with appropriate wavelength activating phototoxicity of the
photosensitizer by generating reactive free radicals. The photo-
toxicity of the illumination can usually affect up to 1–2 cm in
depth [2,3]. The selectivity of PDT toward tumor, mainly
achieved by the selective accumulation of these photosensitizers
within tumor tissue and their activation after light exposure, is
usually quite poor and becomes one major issue that limits the
wider application of PDT as a treatment modality [4]. Many
photosensitizers used in PDT nowadays have limited selectivity for
malignant cells, and thus significant amount of photosensitizer can
be uptaken by normal tissues including skin which maybe one of
the reason leading to skin photosensitivity. New generations of
photosensitizers with better tumor selectivity are under active
development in recent years [5,6,7].
We previously described a peptide-conjugated photosensitizer
(ZnPc-(Lys)5), zinc phthalocyanine (ZnPc) conjugated with penta-
lysine peptidyl moiety, and reported its in vitro and in vivo efficacy
[8]. The pentalysine peptide renders water solubility of ZnPc that
is otherwise not soluble in physiological condition and requires
specialized formulation with, e.g., Cremophor EL. In addition, the
positive charges of pentalysine carries under physiological
condition may provide the selectivity towards tumor, which
carries more negative charges on the cell surface due to its active
metabolism compared to normal cells. Indeed, this photosensitizer
showed 2- and 6-fold selectivity for tumor over muscle and brain
tissues respectively on S180 tumor-bearing mice [8].
In this study, a gonadotropin-releasing hormone (GnRH), also
referred to as LHRH (luteinizing hormone-releasing hormone),
was used as receptor-targeting peptide. GnRH is a hypothalamic
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responsible for the release of follicle-stimulating hormone and
luteinizing hormone from the anterior pituitary via its specific G-
protein coupled GnRH receptor [9]. Notably, GnRH receptors
are found aberrantly expressed in sex steroid-dependent tumors
including breast, ovarian, endometrial, and prostate tumors
[10,11]. In view of the abundance GnRH receptor on these
tumors, targeted chemotherapy based on GnRH analogues has
gained considerable attention. However, the GnRH analogs show
only moderate inhibition of tumor grow (15–20% inhibition after
three to four days of treatment), making them not particularly
useful for the treatment of breast cancer [9,12].
On the other hand, various cytotoxic compounds conjugated
with GnRH analogues have been evaluated for their anticancer
activities. They exhibited a wide range of specific binding affinities
toward cell surface GnRH receptors and could also be internalized
by the cells [13,14,15]. In addition, attaching GnRH analogues to
magnetic nanoparticles, such as iron oxide [12,16] and iron-
platinum nanoparticles [17], were reported to be able to facilitate
their accumulation in cancer cells by targeting the GnRH
receptors. Unfortunately, these conjugates were found to have
serious side effects including the damage to normal pituitary
gonadotropes which is probably due to their high penetration
through blood-brain barrier and concomitant binding to healthy
cells. Although the damage to pituitary cells was reported to be
reversible [18], the use of these conjugates for treatment of
malignancies should be carefully considered.
Our previous work showed that ZnPc has a very low level of
distribution in murine brain [8], thus the ligation of ZnPc to
GnRH may reduce the penetration of the conjugate through
blood-brain barrier, and minimize the side effect of GnRH in
brain. Herein we report the synthesis and the physicochemical
characterization of this ZnPc-GnRH conjugate, along with the
evaluation of its photodynamic activity at cellular level. Our results
clearly demonstrate the selective cellular uptake and cellular
phototoxicity of ZnPc-GnRH conjugate that are mediated by the
cell surface GnRH receptor. This work paves a road for future in
vivo studies.
Materials and Methods
Synthesis and Purification of GnRH Conjugate
Mono-substituted b-carboxyphthalocyanine zinc (ZnPc-
COOH, 5) was synthesized first as previously described [19].
ZnPc-GnRH conjugate (7) was then prepared by coupling 5 with
side chain protected GnRH peptide on Wang resin (as shown in
Scheme S1). Typically, ZnPc-COOH (9.3 mg, 0.015 mmol) was
dissolved in N’N-dimethylformamide (DMF, 1.5 ml) first and
incubated with carboxyl activation agent hexafluorophosphate
tetramethylurea (HBTU, 23.1 mg, 0.06 mmol) and a base N, N-
Diisopropylethylamine (DIEA, 0.093 ml) for 30 min at room
temperature. Side chain protected GnRH peptide (50 mg,
0.015 mmol) on Wang resin (GL Biochem Ltd., Shanghai, China)
was added into the solution and the mixture was kept stirring over
night at room temperature to allow the reaction to complete. After
that, the Wang resin was washed with DMF followed by methanol.
To cleave the coupled product from the Wang resin and to cleave
the protecting groups from the side chain of GnRH, the resin was
soaked in 95% trifluoroacetic acid (TFA) for 4 hr. Crude product
7 was then precipitated by adding dried ether and the solvent was
stripped off under vacuum. The compound 7 was further purified
on a preparative HPLC (Dalian Elite Analytical Instruments Co.
Ltd., Dalian, China) using a SinoChrom ODS-BP column
(250620 mm, 10 mm), eluting with a linear gradient of 10 to
100% acetonitrile (in water solution) during a period of 25 min at
a flow rate of 5 ml/min. The final product 7 has high purity of
99.3% but the yield after purification was low (17.4% based on
compound 5). The low yield is partly due to the lost during
purification, but also probably reflecting the heterogeneity of the
GnRH peptide synthesized on resin.
Characterization of GnRH Conjugate
ZnPc-GnRH conjugate (7) was characterized by ESI-MS
(DECAX-30000 LCQ Deca XP),
1H-NMR (Bruker AV-400,
400 MHz, [D6] DMSO) and FT-IR (Magna-IR 750, Nicolett,
KBr). ESI-MS results (Fig. S1): found m/z [M+H]
+ =1806.1;
calcd m/z for C88H90N24O16Zn [M+H]
+ =1806.2.
1H-NMR
(Fig. S2,[ D 6] DMSO): d =14.3 (s, 2H), 11.5 (s, 1H), 10.8 (s, 1H),
6.5–10 (m, 38H), 5.8 (s, 1H), 2.7–5.2 (m, 25H), 2.4–1.2 (m, 15H),
0.9 (m, 6H) ppm. FT-IR results (Fig. S3): u=3271 cm
–1 (N-H
stretch), 1653 cm
–1 (amide I), 1530 cm
–1 (amide II), 1202 cm
–1
(COO
2 stretch). In addition, UV/Vis absorption spectrum of
ZnPc-GnRH conjugate in dimethyl sulfoxide (DMSO) was
recorded from 400 to 800 nm using quartz cuvettes with 1 cm
path length on a Lambda-35 UV/Vis spectrometer (PerkinElmer,
Massachusetts, USA) [lmax(e) =684 nm, molar extinction coeffi-
cient: 312880 Lmol
21 cm
21)]. Analytical HPLC was carried out
on a C18 RP HPLC system (Dalian Elite Analytical Instruments
Co. Ltd., Dalian, China; column: SinoChrom ODS-BP,
25064.6 mm, 5 mm) using a linear gradient of 10 to 100%
acetonitrile at a flow rate of 1 ml/min.
Photophysical Properties of GnRH Conjugate
Fluorescence quantum yield (Ff) of ZnPc-GnRH conjugate
was measured by a comparative method using ZnPc as a













where Ff and F0 are fluorescence quantum yields of the
conjugate and standard, respectively. Au and A0 are absorbances
of the conjugate and standard, respectively. Fu and F0 are areas
under the emission curves of the conjugate and standard,
respectively. nu and n0 are refractive indices of the solvents used
for the conjugate and standard, respectively. The fluorescence of
the conjugate and standard were measured on a Cary Eclipse
Fluorescence spectrophotometer (Varian, Inc., Walnut Creek,
CA).
Fluorescence decay time (ts) of ZnPc-GnRH conjugate was
measured by time-correlated single photon counting experiment of
fluorescence excited with a 1.2 ns pulse laser diode at 460 nm,
performed on an Edinburgh Instruments FLS920 spectrofluorom-
eter (Livingston, UK) at 300 K. Fluorescence lifetimes were
estimated by fitting the decay data using an interactive deconvolu-
tion procedure based on Marquardt algorithm with software
supplied by OriginLab.
Singlet Oxygen Quantum Yield Determination
The PDT effect of ZnPc type photosensitizer is usually mediated
by type II mechanism involving singlet oxygen (
1O2) as major
cytotoxic agent. The quantum yield of
1O2 generation by ZnPc-
GnRH was determined by comparing with the un-substituted zinc
phthalocyanine (ZnPc) as reference [8], which has a quantum yield
of 0.67 in DMSO [21]. Briefly, a 2 ml DMSO solution of the
mixture of the ZnPc-GnRH conjugate (0.5 mM) and 1,3-
diphenylisobenzofuran (DPBF, a scavenger molecule for
1O2),
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and illuminated with a laser light (670 nm at 80 mW cm
22) in the
presence of air (without degassing). The DPBF decay at 417 nm
was monitored every 5 s. The concentration of DPBF was kept
lower than 3610
25 M during the experiment to avoid chain
reactions induced by DPBF in the presence of
1O2. The quantum
yield measurement has an error of less than 10%.
Cell Lines and Culture Conditions
The cell lines we used in the current study were human breast
cancer cell lines (MDA-MB-231 and MCF-7), human hepatoblas-
toma cell line (HepG2) and human embryo lung fibroblasts
(HELF). All these cell lines were purchased from American Type
Culture Collection (ATCC, Manassas, VA, USA).
MDA-MB-231 and MCF-7 cells were maintained routinely in
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with
10% fetal calf serum (FCS) and antibiotics. HepG2 and HELF
cells were grown in RPMI-1640 supplemented with 10% FCS and
antibiotics. All cells were kept at 37uC in a humidified incubator
with 5% CO2 atmosphere. The viability of cells was determined by
Trypan blue dye exclusion. Cells were maintained in logarithmic
phase with viability .95%.
Cellular Uptake of ZnPc-GnRH Conjugate
Aliquots of cells (2.5610
5 per ml growth medium) were placed
in 96-multiwell black opaque plates (Costa) and incubated







24.5 M) of ZnPc-GnRH
conjugate (in 1% DMSO) or ZnPc-COOH (in an additional 0.2%
Cremophor EL) were added and incubated with cells at 37uC.
After 12 hr incubation, the exponentially growing cells were
washed with sterile PBS before lysis with NaOH (0.1 N, 0.2 ml
with 1% SDS) to give a homogenous solution. The fluorescence of
the cell extract was measured on a microplate reader (Synergy 4,
BioTek Instruments) with lex =610 nm and lem =690 nm. The
concentration of cellular protein was determined with a BCA
Protein Assay Kit (BioTeke Corporation, Beijing, China). Stan-
dard curves were made with cell lysates treated as above with
known added amounts of bovine serum albumin. Results are
expressed as nmol photosensitizer per mg cell protein.
Uptake of ZnPc-GnRH Conjugate on MCF-7 in the
Presence of a GnRH Antagonist
200 ml of MCF-7 cells (at a density of 2.5610
5 per ml) were
seeded in each well of 96-multiwell black opaque plates and
incubated overnight at 37uC under 5% CO2. After treated with or
without Cetrorelix (at a concentration of 7.5610
27 M), a GnRH
antagonist, for 12 hr at 37uC, MCF-7 cells were washed twice with
sterile PBS before fresh medium was added. These exponentially
growing MCF-7 cells were then allowed to incubate with ZnPc-
GnRH conjugate (at a concentration of 5610
26 M) for various
time periods (5, 10, 20, 40, 80, 120 and 180 min) before the
cellular uptakes were measured at different incubation time points
as described above to determine the cellular uptake curves.
Phototoxicity and Dark Toxicity of ZnPc-GnRH Conjugate
Cells at a density of 2.5610
5 per ml in a volume of 200 ml per
well were placed in 96-multiwell black opaque plates and
incubated overnight at 37uC under 5% CO2. One column of
wells did not receive cells to serve as a blank. The cells were







24.5 M) for 12 hr. One
control column in the plate was filled with conjugate-free culture
medium. The cells were then washed twice with sterile PBS before
fresh medium was added. The plates were illuminated at a light
dosage of 1.5 J cm
22 using a 670 nm SAS-DL3 medical laser
(Beijing Shou’anshan Electronic Technology Co. Ltd. Beijing,
China) and then returned to incubator; dark toxicity was measured
in parallel. After 24 hr incubation, cell viability was measured on a
microplate reader (Synergy 4, BioTek Instruments) using the
AlamarBlueH fluorometric cell viability assay (BioSource Interna-
tional Inc., Camarillo, CA, USA) with lex 530 nm and lem
585 nm. The average fluorescence reading of the blank wells was
subtracted from the readings of the wells containing cells. Four
replicates in each drug dosage were run for each cell line, and each
experiment was repeated four times. The cell phototoxicity curves
were plotted as a function of drug dose, and IC50 values were
calculated.
Statistics
Statistical analysis was performed using GraphPad Prism,
version 4.0 (GraphPad Software Inc. San Diego, CA). Quantita-
tive data were expressed as mean 6 standard error (SE) from at
least three independent experiments and assessed using a one-way
ANOVA and a Newman-Keuls test. A probability value of
p,0.05 was considered statistically significant.
Results
Synthesis and Characterization of ZnPc-GnRH Conjugate
ZnPc-GnRH conjugate (7) was prepared by coupling mono-
substituted b-carboxyphthalocyanine zinc (ZnPc-COOH, 5) with
side chain protected GnRH peptide on Wang resin (Scheme S1).
The conjugate was then de-protected and cleaved from the resin
and purified by reversed-phase HPLC to a purity of 99.3% judged
by the absorption of ZnPc at 670 nm (Fig. 1 inset). The structure
of ZnPc-GnRH conjugate was confirmed by ESI-MS (Fig. S1),
1H-NMR (Fig. S2) and FT-IR (Fig. S3).
The UV/Vis absorption spectrum of ZnPc-GnRH conjugate in
DMSO (I in Fig. 1) showed a maximum absorption at 684 nm
and a shoulder peak at 677 nm. The extinction coefficient was
determined to be 312880 L mol
21 cm
21 for the 684 nm peak, in
agreement with previous ZnPc conjugates [8,19,22]. The fluores-
Figure 1. Absorption (I) and fluorescence emission (II, excita-
tion wavelength =608 nm) spectra of ZnPc-GnRH (0.5 mM) in
DMSO. The inset is the C18 reversed-phase HPLC chromatogram.
doi:10.1371/journal.pone.0037051.g001
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also measured (II in Fig. 1) and showed a maximal emission peak
at 696 nm with excitation at 608 nm. ZnPc-GnRH conjugate can
also be excited at 360 nm but with an emission peak height of only
10% of the peak with excitation at 608 nm.
We also measured some photophysical parameters of ZnPc-
GnRH conjugate in DMSO, which includes the fluorescence
quantum yield (Ff) and fluorescence decay time (ts). ts value of
ZnPc-GnRH conjugate was determined based on data-fitting from
the fluorescence decay curve (Fig. 2). As shown in Table 1, Ff
(0.17) and ts (2.7 ns) of ZnPc-GnRH conjugate were comparable
to that of ZnPc reported previously [20,23,24]. Meanwhile, the
singlet oxygen quantum yield (FD) of ZnPc-GnRH conjugate in
DMSO was determined to be 0.73, which is similar to that of
ZnPc (0.67 [21]). All above results indicate that the ligation of the
GnRH peptide with ZnPc photosensitizer does not significantly
alter the photophysical properties of the photosensitizer.
Cellular Uptake of GnRH Conjugate
We chose four cell lines with different levels of GnRH surface
receptors to measure the cellular uptakes of ZnPc-GnRH
conjugate into these cells. The human breast cancer cell lines
(MCF-7 and MDA-MB-231) with over-expressed GnRH receptors
[25,26,27], HepG2 (human hepatoblastoma cells) with a low level
of GnRH surface receptors [28] and HELF (human embryo lung
fibroblasts), a cell line with no expression of GnRH receptor [29]
were used in this study. All these cells are adherent cells. We
incubated these cells with photosensitizer ZnPc-GnRH or GnRH-
free conjugate ZnPc-COOH (as a control for the experiment) for
12 hr along with 1% DMSO (for ZnPc-GnRH) or 0.2%
Cremophor EL (for ZnPc-COOH) that can facilitate the
dissolution of these photosensitizers. The amount of absorbed
photosensitizers inside the cells were measured based on their
fluorescence signals after the unbound photosensitizers around
being washed out. We observed that the cellular uptakes of both
photosensitizers (ZnPc-GnRH and ZnPc-COOH) were increased
with the increasing amount of photosensitizers applied in all four
cell lines above, suggesting that their cellular uptakes are in dose-
dependent manners (Fig. 3).
ZnPc-GnRH conjugate exhibited significantly higher levels of
cellular uptakes in breast cancer cell lines (MCF-7 and MDA-MB-
231) as compared to the other two cell lines (HELF and HepG2)
(Fig. 3a), especially at a higher concentration (10
24.5 M). In
contrast, the unconjugated photosensitizer (ZnPc-COOH) showed
low levels of cellular uptakes by all these four cell lines (Fig. 3b).
The significantly enhanced cellular uptake of ZnPc-GnRH in
breast cancer cells (MCF-7 and MDA-MB-231) over HepG2 or
HELF is likely due to the interaction of ZnPc-GnRH conjugate
with GnRH receptors expressed on the surface of breast cancer
cells.
Reduced ZnPc-GnRH Accumulation on MCF-7 Cells in the
Presence of a GnRH Antagonist
To further confirm the selectivity of ZnPc-GnRH conjugate
towards breast cancer cells is mediated by the GnRH surface
receptor, MCF-7 cells were pre-treated with a GnRH antagonist
Cetrorelix (at 7.5610
27 M) for 12 hr, followed by the monitoring
cellular uptake of ZnPc-GnRH (at 5.0610
26 M) for 2 hr. If
cellular uptake is receptor-mediated, Cetrorelix would be expected
to compete with ZnPc-GnRH for the same binding sites on the cell
membrane and reduce the binding and the internalization of
Figure 2. Room temperature fluorescence decays (=) (excitation wavelength =397 nm) and the fitted curve (–#–) of ZnPc-GnRH in
DMSO.
doi:10.1371/journal.pone.0037051.g002
Table 1. Photophysical parameters of ZnPc-GnRH conjugate
in DMSO compared to that of ZnPc in DMSO.
Ff ts (ns) FD
ZnPc 0.20 [20] 1.22 [23], 3.6 [24] 0.67 [21]
ZnPc-GnRH 0.17 2.7 0.73
doi:10.1371/journal.pone.0037051.t001
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In this particular experiment, Cetrorelix did not completely
displace the uptake of ZnPc-GnRH probably due to the relatively
low amount of Cetrorelix used. It was difficult to use higher
amount of Cetrorelix in the experiment because Cetrorelix peptide
at a higher concentration interferes with ZnPc fluorescence, which
was the readout of the amount of ZnPc absorbed by cells.
It was showed in Fig. 4 that the cellular uptake of ZnPc-GnRH
increased over time and reached the maximal level at approximate
2 hr. This time dependence is consistent with that observed in a
previous experiment using a different GnRH conjugate (GnRH-
protoporphyrin IX [30]).
Phototoxicity and Dark Toxicity of GnRH Conjugate
We measured both phototoxicity and dark toxicity of ZnPc-
GnRH on the four cell lines (MDA-Mb-231, MCF-7, HELF and
HepG2). Consistent with the results we obtained from cellular
uptake experiments, ZnPc-GnRH exhibited remarkable dose-
dependent phototoxicities (%) in both breast cancer cell lines
(MCF-7 and MDA-MB-231, as shown in Fig. 5a and 5b) after
12 hr incubation. The concentrations required to yield 50%
growth inhibition (IC50) were 1.32 mM for MDA-MB-231 and
1.82 mM for MCF-7, respectively. In contrast, no significant
phototoxicity was found in HELF (Fig. 5c) or HepG2 (Fig. 5d)
after 12 hr incubation with ZnPc-GnRH. In addition, no obvious
cellular dark toxicity (&) of ZnPc-GnRH was observed among
these four cell lines, suggesting safety of ZnPc-GnRH in the
absence of light. Putting together, all these results suggest that
ZnPc-GnRH is a highly selective tumor-targeting photosensitizer.
Discussion
The photosensitizer is one of the three key factors that play
critical roles in PDT. Phthalocyanine-based photosensitizers have
attracted increasing attentions for their advantageous properties
compared to the most widely used porphyrin derivatives.
Phthalocyanine has a maximal absorbance around 670 nm, at
which the depth of light penetration in tissue is twice that of
porphyrin at 630 nm [31]. Moreover, phthalocyanine has much
less absorption at solar radiation spectrum (maximum intensity at
475 nm) compared to porphyrin [32], which may lower skin
phototoxicity.
A number of phthalocyanine-based photosensitizers are now
in clinical applications [33,34] or under clinical trials [35].
None of them is a single component compound. Rather, all of
them are mixtures of different phthalocyanine isomers. Such
chemical heterogeneity is the results from the typical statistical
condensation synthetic method for derivatized phthalocyanine.
Recently, there is an increasing interest in synthesizing
phthalocyanine-based photosensitizers with single component,
which facilitate the detailed study of structure-function relation-
ship and is also preferred by drug regulatory agencies. Van Lier
used Kobayashi subphthalocyanine ring expansion reaction to
synthesize 3:1 asymmetrically substituted dodecafluorinated
phthalocyanine, which exhibited an improved photodynamic
activity compared to the symmetric hexadecafluorophthalocya-
nine [36]. Dennis Ng group has made significant contributions
in developing synthetic methods for asymmetric phthalocyanines
without isomers. In their work, phthalocyanine was derivatized
and connected with glycans [37], polyethylene glycols [38] or
Figure 3. Cellular uptakes of ZnPc-GnRH conjugate (a) and free-GnRH photosensitizer ZnPc-COOH (b) after 12 hr incubation with
various cell lines as follows: HELF (N), HepG2 (#), MCF-7 (.) and MDA-MB-231 (g). Values represent the mean of four independent
experiments; bars represent standard error of the mean (SEM).
doi:10.1371/journal.pone.0037051.g003
Figure 4. Time course for accumulation of ZnPc-GnRH conju-
gate in MCF-7 cells at different incubation time points in the
presence (#) or absence (N) of pretreatment with GnRH
antagonist Cetrorelix (7.5610
27 M, 12 hr). Values represent the
mean of four independent experiments; bars represent standard error
of the mean (SEM).
doi:10.1371/journal.pone.0037051.g004
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hydrophilicity of phthalocyanine and the selectivity for tumor
cells. We previously developed a brute approach to generate
pure ZnPc-COOH compound in large quantity [19]. The
carboxy group in ZnPc-COOH allows the ligation of different
targeting agents onto ZnPc-COOH. In this study, we ligate
GnRH peptide to ZnPc-COOH with solid-phase synthesis,
through which many sorts of peptides or oligonucleotides can be
connected with phthalocyanine zinc derivatives.
Besides GnRH analogues, a number of bio-molecules have been
used to guide photosensitizers to tumor cells. Maleylated bovine
serum albumin was conjugated to phthalocyanine and showed
promising results with increased cellular uptakes through macro-
phage scavenger receptor [40]. Similarly, the conjugation of
AlPcS4 with monoclonal anti-carcinoembryonic-antigen antibody
was reported to facilitate the cellular uptake [41]. Nevertheless,
conjugates of peptides to photosensitizers are preferable due to a
number of reasons. Compared to the other bio-molecules, peptides
are usually readily accessible by chemical synthesis and can have
well-defined chemical linkages to photosensitizer. Besides, peptide
could be cleared out quickly, leading to lower background for
imaging purpose. Stefflova et al. conjugated a fluorescent
photosensitizer (Pyropheophorbide A) to a quencher through a
peptide linker (GDEVDGSGK) that can be cleaved by caspase-3,
a key caspase involved in apoptosis [42]. This conjugate
functioned not only as a photosensitizer that leads to photody-
namic effect, but also as a near-infrared imaging agent to detect
cellular apoptosis accompanying photodynamic effect. The
fluorescence of Pyropheophorbide A was quenched by the
quencher in the conjugate. In the events of apoptosis, active
caspase-3 cleaved the peptide linker, thus removed the quencher
and led to the fluorescence signal. Poly-arginine was also used to
conjugate to a photosensitizer (Tetraphenylchlorin, TPC) to
improve the hydrophilicity and cell-penetrability [43]. It was
observed that the cellular uptake of this conjugate was enhanced
about 8 times than that of the unbound photosensitizer. Tirand
and his colleagues reported a conjugate which consisted of TPC,
aminocaproic acid (Ahx) and peptide. The peptide ATWLPPR,
which was identified from phage display screening, can specifically
bind to one of the vascular endothelial growth factor (VEGF)
receptors. Compared to unmodified TPC, the conjugate showed
almost 10 times higher phototoxicity toward human endothelial
cell [44], indicating the potential photodynamic activity through
peptide-mediated VEGF receptor targeting.
In our case, ligation with GnRH analogue does not perturb the
photophysical properties of the parent ZnPc, meanwhile, improves
the ZnPc’s solubility in aqueous circumstance. ZnPc-GnRH
conjugate was found to accumulate preferentially on the cells
expressing a high level of GnRH receptor compared to the cells
with a low expression of GnRH receptor, or compared to
photosensitizer without the targeting peptide (ZnPc-COOH). The
phototoxicity of ZnPc-GnRH conjugate is found specific to
GnRH-receptor-expressing cells.
Furthermore, the UV/Vis absorption spectrum of ZnPc-
GnRH conjugate in DMSO (I in Fig. 1) showed a maximum
absorption at 684 nm and a shoulder peak at 677 nm. For
comparison, the maximal absorption (in DMSO) is at 670 nm
for ZnPc, 674 nm for ZnPc-COOH, 678 nm for pentalysine
phthalocyanine zinc (ZnPc-(Lys)5), and 670 nm for di-sulfonated
di-phthalimidomethyl phthalocyanine zinc (ZnPc-S2P2) [45].
The absorption peak at 684 nm may represent a population
of ZnPc-GnRH molecules where GnRH peptide extends to the
top of the phthalocyanine ring and binds to the central zinc
atom at axial position. Such intramolecular interaction may
then affect the UV absorption peak in a way resemble the
solvent effect on ZnPc absorption [45].
Figure 5. Phototoxicity (%) (at a light dosage of 1.5 Jcm
22) and dark toxicity (&) of ZnPc-GnRH conjugate at various concentrations
after 12 hr incubation with MDA-MB-231 (a), MCF-7 (b), HELF (c), and HepG2 (d). Values represent the mean of four independent
experiments; bars represent standard error of the mean (SEM).
doi:10.1371/journal.pone.0037051.g005
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PLoS ONE | www.plosone.org 6 May 2012 | Volume 7 | Issue 5 | e37051In conclusion, we conjugated a photosensitizer (ZnPc) to a
hormone peptide, GnRH, which is highly expressed in breast
tumors. This ZnPc-GnRH conjugate was prepared to a single
component with a high purity. The cellular uptake and
phototoxicity of the ZnPc-GnRH conjugate were examined with
several cell lines on which different levels of GnRH receptors are
expressed. The cellular uptakes of ZnPc-GnRH conjugate were
found in a dose- and time- dependent manner in all cells, but the
uptakes are much higher in tumor cells than in cells with low levels
of GnRH receptor. The uptake of this ZnPc-GnRH conjugate can
be competed off by a specific GnRH receptor blocker (Cetrorelix),
further supporting that this conjugate is specific to GnRH
receptors expressed on the tumor cell surface. We also demon-
strate the selective phototoxicity toward cells expressing GnRH.
This study thus paves the road for further PDT efficacy study of
GnRH conjugates in animals.
Supporting Information
Figure S1 Mass spectrum of ZnPc-GnRH by ESI HRMS
(DECAX-30000 LCQ Deca XP). m/z peaks at 1806.1 and




Figure S2 Proton nuclear magnetic resonance (
1H-
NMR, Bruker AV-400, 400 MHz, [D6]DMSO) of ZnPc-
GnRH measured in deuterated DMSO and the tentative
assignment of the chemical shifts.
(TIF)
Figure S3 Infrared spectrum of ZnPc-GnRH. The spec-
trum was determined by FT-IR Spectrometer (Magna-IR 750,
Nicolett, KBr). u%=3271 (N-H stretch), 1653 (amide I), 1530




Scheme S1 Synthesis of ZnPc-GnRH conjugate (7) from
the previously described monosubstituted b-carbox-
yphthalocyanine zinc (5, ZnPc-COOH). Reagents and
conditions: a) (NH2)2CO, Zn(OAc)2, (NH4)2MoO4, 170uC, 4 hr;
b) KOH (1 M), 100uC, 24 hr; c) HBTU, DIEA, DMF, 25uC,
24 hr; d) TFA (95%), 25uC, 4 hr.
(TIF)
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